Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of the Oral Cyclin A/B-RxL Inhibitor CID-078 in Patients With Advanced Solid Tumor Malignancies

Next Previous
Trial Profile

A Phase 1, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of the Oral Cyclin A/B-RxL Inhibitor CID-078 in Patients With Advanced Solid Tumor Malignancies

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 30 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CID 078 (Primary)
  • Indications Advanced breast cancer; HER2 negative breast cancer; Male breast cancer; Non-small cell lung cancer; Small cell lung cancer; Solid tumours; Triple negative breast cancer
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Circle Pharma

Most Recent Events

  • 23 May 2025 Planned number of patients changed from 100 to 220.
  • 12 May 2025 According to a Circle Pharma media release, a trial-in-progress poster will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 30 to June 3 in Chicago.
  • 15 Oct 2024 According to a Circle Pharma media release, the company anticipates reporting preliminary safety and anti-tumor data from the Phase 1 study in 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top